AR130094A1 - Inhibidores de inflamasoma nlrp3 - Google Patents
Inhibidores de inflamasoma nlrp3Info
- Publication number
- AR130094A1 AR130094A1 ARP230102029A ARP230102029A AR130094A1 AR 130094 A1 AR130094 A1 AR 130094A1 AR P230102029 A ARP230102029 A AR P230102029A AR P230102029 A ARP230102029 A AR P230102029A AR 130094 A1 AR130094 A1 AR 130094A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- halo
- substituted
- pharmaceutically acceptable
- Prior art date
Links
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 title abstract 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 5
- 125000001475 halogen functional group Chemical group 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- -1 -OH Chemical group 0.000 abstract 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 108091008099 NLRP3 inflammasome Proteins 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), o una de sus sales farmacéuticamente aceptables, en donde R¹ es Cl, CH₃, -OCF₃ o CF₃; R² es halo, alquilo C₁-C₄ o haloalquilo C₁-C₄; R³ es H, CN, alquilo C₁-C₄ o haloalquilo C₁-C₄; R⁴ es -(CH₂)ₙ-OH, en donde n es 1, 2, 3 o 4; R⁵ es un heterociclilo monocíclico o bicíclico, que no está sustituido o está sustituido con 1 a 2 sustituyentes seleccionados independientemente de alquilo C₁-C₄, haloalquilo C₁-C₄, hidroxialquilo C₁-C₄, -OH, halo, oxo y -CO₂H; o R⁵ es un arilo o heteroarilo, que no está sustituido o está sustituido con 1 a 2 sustituyentes seleccionados independientemente de halo, haloalquilo C₁-C₄, alquilo C₁-C₄ y -SO₂NH₂; o R⁵ es cicloalquilo C₃-C₆ que no está sustituido o está sustituido con 1 a 3 sustituyentes seleccionados independientemente de alquilo C₁-C₄, halo, haloalquilo C₁-C₄ y -OH; o R⁵ es alquilo C₂-C₆ sustituido con 1 o más sustituyentes seleccionados independientemente de -OH, alcoxi C₁-C₄, halo, -NH₂, -NH(alquilo C₁-C₄) y -N(alquilo C₁-C₄)₂, o una sal farmacéuticamente aceptable del mismo. Reivindicación 14: Un compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 10, o una sal farmacéuticamente aceptable del mismo, para utilizar en el tratamiento de una enfermedad o trastorno en el que la señalización de NLRP3 contribuye a la patología y/o los síntomas y/o la progresión de dicha enfermedad o trastorno. Reivindicación 17: Un método para inhibir la actividad del inflamasoma NLRP3 en un sujeto que lo necesite, comprendiendo el método administrar a un sujeto que lo necesite una cantidad terapéuticamente eficaz de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 10, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263370300P | 2022-08-03 | 2022-08-03 | |
| CN2023097282 | 2023-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130094A1 true AR130094A1 (es) | 2024-10-30 |
Family
ID=87580191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102029A AR130094A1 (es) | 2022-08-03 | 2023-08-01 | Inhibidores de inflamasoma nlrp3 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20240067627A1 (es) |
| EP (1) | EP4565326A1 (es) |
| JP (1) | JP2025525866A (es) |
| KR (1) | KR20250043519A (es) |
| CN (1) | CN119677725A (es) |
| AR (1) | AR130094A1 (es) |
| AU (1) | AU2023318764A1 (es) |
| CA (1) | CA3262660A1 (es) |
| CL (1) | CL2025000285A1 (es) |
| CO (1) | CO2025002057A2 (es) |
| CR (1) | CR20250063A (es) |
| DO (1) | DOP2025000013A (es) |
| IL (1) | IL318533A (es) |
| MA (1) | MA71689A (es) |
| MX (1) | MX2025001273A (es) |
| PE (1) | PE20251255A1 (es) |
| TW (1) | TW202406550A (es) |
| UY (1) | UY40374A (es) |
| WO (1) | WO2024028782A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2510997A1 (fr) | 1981-08-10 | 1983-02-11 | Sanofi Sa | Nouveaux derives de la methyl-4 phenyl-6 pyridazine, procede pour leur preparation et medicaments actifs sur le systeme nerveux central en contenant |
| PT93060B (pt) | 1989-02-07 | 1995-12-29 | Sanofi Sa | Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem |
| FR2663326B2 (fr) | 1989-11-17 | 1992-10-16 | Sanofi Sa | Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant. |
| FR2676444B1 (fr) | 1991-05-16 | 1995-03-10 | Sanofi Elf | Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant. |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| JP5221952B2 (ja) | 2004-05-08 | 2013-06-26 | ノバルティス・インターナショナル・ファーマシューティカル・リミテッド | ３−アリール−５，６−ジ置換ピリダジン類 |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| WO2008058064A1 (en) | 2006-11-07 | 2008-05-15 | Lexicon Pharmaceuticals, Inc. | Amine-linked multicyclic compounds as inhibitors of the proline transporter |
| GB0720444D0 (en) | 2007-10-18 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| WO2010128152A1 (en) | 2009-05-07 | 2010-11-11 | Novartis Ag | Fused heterocyclic c-glycosides for the treatment of diabetes |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| EP2491050A2 (en) | 2009-10-20 | 2012-08-29 | Novartis AG | Glycoside derivative and uses thereof |
| MX342164B (es) | 2010-06-23 | 2016-09-19 | Hanmi Science Co Ltd | Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa. |
| WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| NZ607845A (en) | 2010-08-10 | 2015-03-27 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
| US8835472B2 (en) | 2010-09-02 | 2014-09-16 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| CA2818903C (en) | 2010-12-14 | 2021-03-23 | Electrophoretics Limited | 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| KR20140007954A (ko) | 2011-06-10 | 2014-01-20 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법 |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| JP5704252B2 (ja) | 2011-11-29 | 2015-04-22 | 小野薬品工業株式会社 | プリノン誘導体塩酸塩 |
| US9353087B2 (en) | 2012-06-08 | 2016-05-31 | Biogen Ma Inc. | Inhibitors of Bruton's tyrosine kinase |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| CN104822681B (zh) | 2012-09-10 | 2018-01-30 | 普林斯匹亚生物制药公司 | 作为激酶抑制剂的吡唑并嘧啶化合物 |
| NZ708501A (en) | 2012-11-28 | 2019-03-29 | Intercept Pharmaceuticals Inc | Treatment of pulmonary disease |
| UY35368A (es) | 2013-03-08 | 2014-10-31 | Irm Llc | Péptidos y composiciones para el tratamiento de daño articular |
| JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| ES2619125T3 (es) | 2013-04-25 | 2017-06-23 | Beigene, Ltd. | Compuestos heterocíclicos fusionados como inhibidores de proteína cinasa |
| LT3065738T (lt) | 2013-11-05 | 2018-05-10 | Novartis Ag | Kompozicijos ir būdai, skirti x receptorių moduliavimui |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| AU2014358868A1 (en) | 2013-12-05 | 2016-06-09 | Acerta Pharma B.V. | Therapeutic combination of a PI3K inhibitor and a BTK inhibitor |
| WO2015092740A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Heteroaryl butanoic acid derivatives as lta4h inhibitors |
| WO2015110923A2 (en) | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| RS59853B1 (sr) | 2014-03-14 | 2020-02-28 | Novartis Ag | Molekuli anti-lag-3 antitela i njihove upotrebe |
| MX377796B (es) | 2014-05-13 | 2025-03-11 | Novartis Ag | Compuestos y composiciones para inducir condrogenesis. |
| CN103965169A (zh) | 2014-05-30 | 2014-08-06 | 彭正中 | 一种化合物及其制备方法与用途 |
| WO2016022626A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| CA2965517C (en) | 2014-10-24 | 2023-05-02 | Bristol-Myers Squibb Company | Indole carboxamides compounds useful as kinase inhibitors |
| BR112017013728A2 (pt) | 2014-12-24 | 2018-03-13 | Principia Biopharma Inc. | dosagem de inibidor da btk a sítio específico |
| EP3247701B1 (en) | 2015-01-20 | 2021-09-22 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic compounds, compositions and method of using thereof |
| WO2016123229A1 (en) | 2015-01-29 | 2016-08-04 | Yale University | Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders |
| WO2016128343A1 (en) | 2015-02-09 | 2016-08-18 | F. Hoffmann-La Roche Ag | Compounds for the treatment of cancer |
| ME03737B (me) | 2015-02-16 | 2021-01-20 | Univ Queensland | Sulfoniluree i srodna jedinjenja i njihova upotreba |
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| MX395007B (es) | 2015-06-03 | 2025-03-24 | Principia Biopharma Inc | Inhibidores de tirosina-cinasas |
| US20180282310A1 (en) | 2015-06-10 | 2018-10-04 | Biogen Ma Inc. | Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase |
| US10533011B2 (en) | 2015-10-09 | 2020-01-14 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
| RU2022100782A (ru) | 2015-11-04 | 2022-02-03 | Мерк Патент Гмбх | Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью |
| HUE055031T2 (hu) | 2015-12-10 | 2021-10-28 | Ptc Therapeutics Inc | Módszerek Huntington-kór kezelésére |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| HK1243419B (zh) | 2016-01-05 | 2019-11-22 | 江苏恒瑞医药股份有限公司 | 一种btk激酶抑制剂的结晶形式及其制备方法 |
| US10787433B2 (en) | 2016-01-15 | 2020-09-29 | The Brigham And Women's Hospital, Inc. | Pyridazine derivatives as EAAT2 activators |
| KR101865120B1 (ko) | 2016-06-29 | 2018-06-08 | 숭실대학교 산학협력단 | 테스트 노드 기반의 무선 측위 방법 및 그 장치 |
| IL293621B2 (en) | 2016-06-29 | 2023-09-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile |
| EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| WO2018232039A1 (en) | 2017-06-14 | 2018-12-20 | Ptc Therapeutics, Inc. | Methods for modifying rna splicing |
| CN120647572A (zh) | 2017-07-07 | 2025-09-16 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| KR102698385B1 (ko) | 2017-07-14 | 2024-08-22 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| GB2579747B8 (en) | 2017-08-04 | 2022-10-05 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
| AU2018317798A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP |
| WO2019060917A2 (en) | 2017-09-25 | 2019-03-28 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR SCREENING AND IDENTIFYING SPREADING MODULATORS |
| EP3694848A1 (en) | 2017-10-12 | 2020-08-19 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| JP2021502364A (ja) | 2017-11-09 | 2021-01-28 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
| CN112135815A (zh) | 2018-03-27 | 2020-12-25 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
| JP2021521200A (ja) | 2018-04-10 | 2021-08-26 | スカイホーク・セラピューティクス・インコーポレーテッド | 癌の処置のための化合物 |
| SG11202104495YA (en) | 2018-04-26 | 2021-05-28 | Aurigene Discovery Tech Ltd | Pyridazine derivatives as smarca2/4 degraders |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| US20230107277A1 (en) * | 2020-03-27 | 2023-04-06 | Astellas Pharma Inc. | Substituted pyridazine compound |
| KR20230035049A (ko) * | 2020-07-02 | 2023-03-10 | 데날리 테라퓨틱스 인크. | 화합물, 조성물 및 방법 |
| CN116390914A (zh) * | 2020-12-25 | 2023-07-04 | 上海拓界生物医药科技有限公司 | 一类含哒嗪的化合物及其医药用途 |
| CN116867769A (zh) * | 2021-02-08 | 2023-10-10 | 南京明德新药研发有限公司 | 取代的哒嗪苯酚类衍生物 |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
-
2023
- 2023-07-27 UY UY0001040374A patent/UY40374A/es unknown
- 2023-08-01 US US18/363,207 patent/US20240067627A1/en active Pending
- 2023-08-01 AR ARP230102029A patent/AR130094A1/es unknown
- 2023-08-01 TW TW112128876A patent/TW202406550A/zh unknown
- 2023-08-02 IL IL318533A patent/IL318533A/en unknown
- 2023-08-02 CA CA3262660A patent/CA3262660A1/en active Pending
- 2023-08-02 AU AU2023318764A patent/AU2023318764A1/en active Pending
- 2023-08-02 MA MA71689A patent/MA71689A/fr unknown
- 2023-08-02 CN CN202380056099.4A patent/CN119677725A/zh active Pending
- 2023-08-02 PE PE2025000269A patent/PE20251255A1/es unknown
- 2023-08-02 EP EP23755486.0A patent/EP4565326A1/en active Pending
- 2023-08-02 KR KR1020257006563A patent/KR20250043519A/ko active Pending
- 2023-08-02 JP JP2025505788A patent/JP2025525866A/ja active Pending
- 2023-08-02 WO PCT/IB2023/057819 patent/WO2024028782A1/en not_active Ceased
- 2023-08-02 CR CR20250063A patent/CR20250063A/es unknown
-
2024
- 2024-10-16 US US18/917,653 patent/US12378222B2/en active Active
-
2025
- 2025-01-29 DO DO2025000013A patent/DOP2025000013A/es unknown
- 2025-01-30 MX MX2025001273A patent/MX2025001273A/es unknown
- 2025-01-30 CL CL2025000285A patent/CL2025000285A1/es unknown
- 2025-02-25 CO CONC2025/0002057A patent/CO2025002057A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20250063A (es) | 2025-03-27 |
| CA3262660A1 (en) | 2024-02-08 |
| DOP2025000013A (es) | 2025-02-28 |
| MX2025001273A (es) | 2025-03-07 |
| US20240067627A1 (en) | 2024-02-29 |
| CN119677725A (zh) | 2025-03-21 |
| KR20250043519A (ko) | 2025-03-28 |
| AU2023318764A1 (en) | 2025-01-09 |
| JP2025525866A (ja) | 2025-08-07 |
| WO2024028782A1 (en) | 2024-02-08 |
| CO2025002057A2 (es) | 2025-03-06 |
| US12378222B2 (en) | 2025-08-05 |
| CL2025000285A1 (es) | 2025-06-13 |
| IL318533A (en) | 2025-03-01 |
| US20250034114A1 (en) | 2025-01-30 |
| MA71689A (fr) | 2025-05-30 |
| EP4565326A1 (en) | 2025-06-11 |
| UY40374A (es) | 2024-02-15 |
| TW202406550A (zh) | 2024-02-16 |
| PE20251255A1 (es) | 2025-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR130094A1 (es) | Inhibidores de inflamasoma nlrp3 | |
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| CO2022012975A2 (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
| MX2022011283A (es) | Compuestos pirimidoheterocíclicos y aplicación de los mismos. | |
| EA202092169A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2 | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| AR044818A1 (es) | Acidos pirrolidin 1-2 dicarboxilicos-1-[4-(etinil-fenil)amida]-2-[(fenil)-amido] derivados y procedimiento para preparar dichos compuestos | |
| AR133988A1 (es) | Inhibidores de ras-pi3k y usos de los mismos | |
| AR133968A1 (es) | Nuevo compuesto derivado de ftalazina como inhibidor de sos1 y uso del mismo | |
| AR080859A1 (es) | Derivados 1,2,4 triazolo-piridinicos inhibidores no nucleosidicos de la transcriptasa inversa, utiles para tratar infecciones por vih y composiciones farmaceuticas que los contienen. | |
| RU2015143841A (ru) | Ингибиторы hdac | |
| AR123355A1 (es) | Inhibidores de apol1 y métodos para usar los mismos | |
| AR115965A1 (es) | Derivados heteroaromáticos de carboxamida como inhibidores de la calicreína plasmática | |
| PE20252238A1 (es) | Derivados de n-fenil-pirazolo[1,5-a] piridina-3-carboxamida como inhibidores de la c-kit quinasa de tipo salvaje para el tratamiento de la urticaria | |
| AR125122A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| AR131639A1 (es) | Inhibidores de kif18a y usos de los mismos | |
| CO2024010542A2 (es) | Inhibidores de apol1 y métodos de uso | |
| AR127948A1 (es) | Inhibidores de aldosterona sintasa para tratar la enfermedad renal crónica | |
| DOP2025000009A (es) | Inhibidores de acc novedosos | |
| AR128066A1 (es) | Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos | |
| AR125608A1 (es) | Novedosos compuestos útiles como agonistas de sting y sus usos | |
| AR125120A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| AR129846A1 (es) | Agonistas de trpml1 con oxazol y usos de estos | |
| PE20250419A1 (es) | Compuestos antivirales y metodos de elaboracion y uso de los mismos | |
| AR038094A1 (es) | Derivados de benzotiazol-4,7-dionas y benzooxazol-4,7-dionas, su uso para preparar un medicamento y composicion farmaceutica |